Tile: Combination Therapy of Zinc and Trimethoprim Inhibits Influenza A Virus In Chick Embryo

Magdi El Habbal (elhabbel@elhabbel.karoo.co.uk)
Mastropix Health Care  https://orcid.org/0000-0001-8694-0439
Magdi H El Habbal
Mastropix Health Care

Research

Keywords: Chick embryo, influenza virus, trimethoprim, Zinc, Hemagglutination

DOI: https://doi.org/10.21203/rs.3.rs-118266/v2

License: ©  This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Background. Respiratory RNA viruses including influenza virus have been a cause of health and economic hardships. These viruses depend on its host for replication and infection. Influenza virus infection is lethal to the chick embryo. We examined whether a combination of trimethoprim and zinc (Tri-Z), that acts on the host, can reduce the lethal effect of influenza A virus in chick embryo model.

Method. Influenza virus was isolated from patients and propagated in eggs. We determined viral load that infects 50% of eggs (50% egg lethal dose, ELD50). We introduced 10 ELD50 into embryonated eggs and repeated the experiments using 100 ELD50. A mixture of zinc oxide (Zn) and trimethoprim (TMP) (weight / weight ratios ranged from 0.01 to 0.3, Zn/TMP with increment of 0.1) was tested for embryo survival of the infection (n = 12 per ratio, in triplicates). Embryo survival was determined by candling eggs daily for 7 days. Controls of Zn, TMP saline or convalescent serum were conducted in parallel. The effect of Tri-Z on virus binding to its cell surface receptor was evaluated in a hemagglutination inhibition (HAI) assay using chicken red cells. Tri-Z was prepared to concentration of 10 mg TMP and 1.8 mg Zn per ml, then serial dilutions were made. HAI effect was expressed as scores where ++++ = no effect; 0 = complete HAI effect.

Results. TMP, Zn or saline separately had no effect on embryo survival, none of the embryos survived influenza virus infection. All embryos treated with convalescent serum survived. Tri-Z, at ratio range of 0.15 to 0.2 (optimal ratio of 0.18) Zn / TMP, enabled embryos to survive influenza virus despite increasing viral load (>80% survival at optimal ratio). At concentration of 15 microgram/ml of optimal ratio, Tri-Z had total HAI effect (scored 0). However, at clinical concentration of 5 microgram/ml, Tri-Z had partial HAI effect (++)

Conclusion. Acting on host cells, Tri-Z at optimal ratio can reduce the lethal effect of influenza A virus in chick embryo. Tri-Z has HAI effect. These findings suggest that combination of trimethoprim and zinc at optimal ratio can be provided as treatment for influenza and possibly other respiratory RNA viruses infection in man.

Introduction

Respiratory RNA viruses are continuing to challenge man with epidemics and devastating pandemics. RNA and DNA synthesis require polymerase enzymes. While DNA polymerases have read-proof abilities with correction facilities, RNA polymerases do not have such qualities whereby errors, i.e. mutations, occur [1]. Some of these mutations may allow RNA virus to cross species like SARS and COVID-19 whereby no vaccination existed. Mutations of influenza virus continue to cause yearly epidemics and, in 1918 and 2009, instigated pandemics [2].

Influenza virus can adapt to species specific haemagglutinin biding receptors on cell surface and then cross the species [3]. Crossing species is a threat to national and international public health with devastating health and socioeconomics burdens [4]. In the wrong hands, a technology involving respiratory RNA viruses may become a threat to national security. Public health education, vaccination and drug treatment are strategies whereby national security against threats of respiratory RNA virus pandemics is ensured.

In anticipation of the threats, we embarked on development on an anti-viral. We identified trimethoprim (TMP) and zinc (Zn) as potential candidates for treatment for RNA virus. RNA virus requires host cell wall receptors to infect and its nucleus to replicate [2]. TMP inhibits folate dehydrogenase where-by it affects nuclear DNA with deleterious effect on the cell and its wall [5]. In man, the effect is transient and mostly subclinical [6]. Zinc ions were demonstrated to inhibit RNA virus, rhinovirus [7]. When combined at a ratio TMP and Zn may treat respiratory RNA virus infections [8].

There are several respiratory RNA viruses including influenza virus, Coronavirus, Respiratory Syncytial virus and rhinovirus [9]. To infect, these viruses require attaching to the host cell surface receptors, internalization and replication using the host nucleus and intracellular organelles [2, 8, 9]. We used influenza virus as a model because it shares similar mechanisms for infection, replication and pathogenesis with that of the respiratory RNA viruses [3, 9].

Studies of influenza virus are usually carried out in ferret and/or mouse models. However, ferrets and mice are more susceptible to zinc toxicity than other species such as the chick embryo [10, 11]. The chick requires zinc for normal development and can tolerate high intake of zinc supplied in appropriate diet [12, 13]. Influenza virus infection is lethal to the chick embryo. Chick embryo is easy to access as a culture medium, highly susceptible to influenza virus, of low cost and was shown to be a reliable model for testing anti-influenza drugs [14, 15]. In this study we examined the use of combination of TMP and Zn on chick embryo survival to influenza infection.

Methods

We isolated influenza virus from positive swabs from patients during influenza season and propagated it in white leg horn embryoate eggs. Virus detection was carried out using florescence immune assay (FIA) and its subtypes identified by using PCR (RT-PCR) as previously described [16, 17].

Virus isolation

Virus was isolated from positive patient’s swabs during influenza season. Virus strain identification was conducted as previously described [18]. We identified the strain H3N2 [A/England/215/2011 (H3N2) like-virus].

We used embryonated eggs as described by and according to WHO guidance for virus isolation and detection [19, 20]. Briefly, eggs were incubated at 33-35 °C and 70% humidity with air sac facing upward (to allow embryo development at the air sac position for ease of visualization). The choice of 33-35 °C is to allow optimal viral multiplications [21]. Eggs were candled daily to check for embryo growth. Before inoculation, the stage of development was determined by direct inspection through a window in the egg shell using Olympus dissecting microscope. Eggs that did not show live embryos at matching stage of
development were removed and discarded. The stage of development was determined according to Hamburger and Hamilton [22]. Thus, embryos were tested at the same stage of development. On day 8 of incubation (Hamburger and Hamilton stage 34) eggs were used for virus isolation.

Influenza positive material (0.2 ml) was mixed with broad spectrum antibiotic. The material was injected via the window using 22-gauge needle into amniotic and allantoic space. The window was sealed using bees wax. Eggs were candled daily to detect embryos survival. At day 11 of incubations, eggs were removed from incubator and placed in fridge at 4 °C for 1 hour to reduce the likelihood of bleeding from allantoic membrane. The presence of the virus was determined by hem-agglutination (HA) test [23, 24].

We repeated the passage in chick embryos 3 times. From the last passage, allantoic fluids were collected to make a stock of the virus. The stock was tested for presence of the virus using standardized HA technique. Aliquots were made and stored in -70 °C till used.

**Determination of 50% egg infective dose (EID\(_{50}\))**

We made by inoculating 0.1 ml of serial 10-fold dilutions of virus. Eggs were incubated at 36 °C and candled daily to detect embryo survival. On day 8 on incubation, we injected 0.1 ml of the virus into the allantoic cavity. The eggs were returned to the incubator for further 48 hr at 36 °C. Eggs were opened to determine embryo survival or death. The allantoic fluid from each egg, was tested for the virus by HA test. We used 12 eggs per dilution and repeated the experiments 3 times. The dilution that caused 50% death of embryos (egg infectious doses, EID\(_{50}\)) was determined using survival and death as described by Reed and Muench [25]. We calculated the dilution that contain 100 EID\(_{50}\) according to the equation: Log dilution of virus suspension containing 100 EID\(_{50}\) = Log EID\(_{50}\) + 2.

**Determining effect of Tri-Z**

Summary of the study protocol and groups are shown in figure 1 and table 1, respectively.

The effect of Tri-Z on influenza virus was tested using embryo survival as measure of effectiveness. For these experiments, we used eggs at day 6 of incubation (Hamburger and Hamilton stage 29) because it is a vulnerable (interferon deficient) period for the embryo [26]. The outcome of treatment is measured by percentage of survival (effective) or death (ineffective) of the embryos 7 days after inoculation.

**Table 1.** It shows study groups. We carried experiments examining effect of a mixture of trimethoprim and zinc. influenza virus. We examined two virus loads 10 EID\(_{50}\) and 100 EID\(_{50}\), in 6 day old chick embryos, group 1 and group 2. This was compared to control groups (C 1- C 4). Experiments were repeated in triplicates. EID\(_{50}\) = egg infective dose 50 i.e. virus load that cause 50% mortality of the embryo, C = control, NS = normal

| Group | Virus load | treatment | number of embryos |
|-------|------------|-----------|-------------------|
| group 1 | 10 EID\(_{50}\) | Tri-Z: at Zn/TMP ratio 0.01 to 0.3, increment of 0.01 (30 ratios) | 12 per ratio |
| group 2 | 100 EID\(_{50}\) | Tri-Z: at Zn/TMP ratio 0.01 to 0.3, increment of 0.01 (30 ratios) | 12 per ratio |
| C 1 | 10 EID\(_{50}\) | .5 ml NS | 12 |
| C 2 | 10 EID\(_{50}\) | Zn: 0.05 to 1.5 mg with 0.05 mg increments (30 concentrations) | 12 per concentration |
| C 3 | 10 EID\(_{50}\) | TMP: 5 mg | 12 |
| C 4 | 10 EID\(_{50}\) | 0.2 ml of convalescent serum | 12 |

Embryo survival was determined as heart is beating, and embryo is moving. Death of the embryo was recorded as being the breakdown of the visible blood vessel structures of the chorioallantoic membrane, the appearance of disseminated coagulation, blood leakage into the yolk or the allantoic fluid areas, the absence of heart beating, absence of movement of the embryo, and extensive autolysis [27].

All experiments were repeated three times to ensure reproducibility.

We made suspensions from mixture of TMP and Zn (Tri-Z). The Zn/TMP ratio ranged from 0.01 to 0.3 with increment of 0.01. TMP powder (Medex, UK) was suspended in sterile water at concentration of 10 mg/ ml. We added Zn oxide powder (Medex, UK) to generate the desired mixture ratio. We made fresh suspension/s prior to each experiment. It was shaken to allow for homogeneous distribution of the compounds. We tested 30 ratios with 12 eggs in each ratio group.

**Study groups**

On day 6 of egg incubation, the combined suspension was injected (0.5 ml) into the air sac using plastic syringe through an 18-gauge needle. An hour later, 10 EID\(_{50}\) was injected into the allantoic space as close as possible to the embryo (group 1). Eggs were returned to the incubator and candled daily for 7 days to determine embryo survival.

To evaluate the effect of increasing viral load, we repeated the same experiments but using 100EID\(_{50}\) virus suspension, (group 2).
Controls

To verify the effects of Tri-Z on influenza virus, we carried out similar experiments in controls groups, at Hamilton and Hamburger stage 29 (day 6 of incubation). In each experiment, 12 fertilized eggs were used. We followed the study protocol but the test material varied based on the control group.

First control (C1): The test material was an increasing dose of Zn (in 0.5 ml saline, to match the amount of Zn in the respective ratio but without TMP) was injected into eggs in similar fashion.

Second control (C2): we used TMP only at a dose of 5 mg in .5 ml saline.

Third control (C3): we injected 0.5 ml of normal saline into the eggs.

Fourth control (C4): To ensure that death of embryo occurred from viral infection, virus infected eggs (10 EID\textsubscript{50}) were incubated with and without neutralizing antibodies using periodate treated convalescent serum (0.5 ml) from the patient as previously described [24].

Hemagglutination (HA)

As previously described [23, 24], hem-agglutinin titrations were carried out by adding 0.2 ml of a 0.5 % suspension of washed fowl erythrocytes (RBCs) to 0.2 ml of each serial two-fold dilution of test material. The tests were read after 45 minutes at room temperature. The end point was the highest dilution showing complete HA which contains 1 HA unit (HAU) / 0.05 ml.

Hemagglutination inhibition (HAI)

We carried out HAI as previously described [24] with Tri-Z as the test material. Tri-Z was prepared to concentration of 10 mg TMP and 1.8 mg Zn per ml, then serial dilutions were made. We added equal volumes of Tri-Z to that of 4 HAU of virus. Then, fowl RBCs were added. The final mixture was incubated for 30 min at room temperature before reading [23]. To verify that the effect of Tri-Z is on the cell and not the virus, we repeated the same experiment except that the RBCs were incubated with Tri-Z for 30 min, and then washed in PBS prior to addition to the virus. Results were expressed as previously described, where no HA = 0, some HA = +, partial HA = ++, more than partial HA = ++++, complete HA= +++++ [23, 24].

Statistics

We used the number of embryos surviving at day 7 after infection as a measure of the outcome of treatment. Data were tested for normality of distribution, and then parametric or non-parametric tests were applied accordingly. If data were normally distributed, we applied paired test to determine the significance of change in ratio on the survival of embryos. Where data were abnormally distributed, we applied Mann-Whitney test. To determine the significance of difference in survival with change in ratio we applied repeated analysis of variance. Chi square test was applied to identify the most significant ratio at which highest survival was achieved. Significance value was set at p < 0.05 [28, 29].

Results

The virus isolated from patients was influenza virus H3N2 [A/England/215/2011(H3N2) like-virus infection].

At viral load of 10EID\textsubscript{50}, there was no embryo survival at ratios 0.01 to 0.04 and 0.26 to 0.3. Embryo survival occurred at 0.05 to 0.25 ratios. At viral load of 100EID\textsubscript{50}, there was no embryo survival at ratios of 0.01 to 0.14 and 0.21 to 0.3; embryo survival occurred at ratio of 0.15 to 0.2. The effect of changing Zn to TMP ratio on embryo survival is shown in figures 2 and 3. The effect of increasing viral load on embryo survival is shown in figure 4.

It appeared that with increasing the ratio of Zn to TMP embryo survival increased. It peaked at ratio about 0.18 (Zn/TMP). There was decrease in the survival with further increase in the ratio. The data were normally distributed. The changes in Zn to TMP ratio had significant effect on the survival of the embryos, p < 0.001. In cluster analysis, it seemed that there were three clusters, with one cluster showing much better survival than the other two clusters, p < 0.001. In that cluster, the range of effective ratio was 0.1 to 0.2. The peak of surviving embryos was at ratio of .18, figure 2. With increasing viral load to 100 EID\textsubscript{50}, the cluster distribution was abolished. Embryo survival was possible in Zn/TMP ratio range 0.15 - 0.2, with the peak survival at ratio of 0.18, figure 3.

In C1, C2 and C3 groups, all embryos died. In C4, embryos survived which confirms that death of the embryos was a result of influenza virus infection.

The results from HAI studies whereby Tri-Z was mixed with the virus prior to addition RBCs and that where Tri-Z was incubated with RBCs prior to addition to the virus were the same. The highest dilution of the virus stock that caused HA was 1/4096, thus containing 1HAU. The dilution used that contained 4 HAU was 1/1048. It was possible to achieve total HAI (score of 0) with Tri-Z at 15 microgram / ml. However, at 5 microgram / ml, HAI was partial scoring ++ comparing to controls of virus scoring ++++ and without virus scoring 0. Neither Zn nor TMP separately had any observable HAI effect (scoring ++++) similar to control virus, table 2 and figure 5.

Table 2. It shows that Tri-Z, at ratio 5 mcq/ml, had hem-agglutination inhibition effect scoring ++ comparing to TMP or Zn separately; - means no hem-agglutination, ++++ mean total hem-agglutination. Serum preparation from patients and hem-agglutination were carried out as previously described [23, 24].
Agent | Hemagglutination
---|---
saline | -

| Agent | Hemagglutination |
|-------|------------------|
saline | - |
virus  | ++++ |
serum and virus | - |
Tri-Z and virus | ++ |
TMP and virus | ++++ |
Zn and virus | ++++ |

Discussion

This study shows that a combination of TMP and Zn (Tri-Z) can treat influenza virus infection in chick embryo independent of interferon. Six days old chick embryos treated with Tri-Z survived the virus, comparing to controls. In 6 day old chick embryo, interferon is deficient [26] and the viral infection is lethal.

Like other RNA viruses, influenza virus depends on its host cell and nuclear DNA for replication and spread [3], which is associated with an increase in amino acid synthesis [30]. Excluding host nuclear DNA by enucleation of cells prevents RNA virus replication [31, 32]. Interfering with host DNA by TMP (which is a dihydro-folate reductase enzyme inhibitor) can disturb the host processes for viral replication. While in bacteria, TMP affects DNA to a point that causes arrest of cell division (bacteriostasis) in man the effect is transient [6]. It was reported that TMP may have beneficial effect in treating DNA virus infections [33, 34]. However, for RNA virus, TMP on its own is not effective. All embryos treated with TMP alone did not survive the infection, but with Zn, the combination was effective.

Zinc was shown to inhibit replication of RNA virus, rhinovirus, in vitro [7]. In vivo, the effect was not quiet evident but thought to assist in ameliorating rhinovirus infections (common cold) [35]. In chick embryo, zinc did not inhibit influenza virus. All embryos treated with Zn alone died from influenza virus infection. But, with TMP, the combination enabled embryo survival of influenza virus.

Zinc ions are key structural components of a large number of proteins. In eukaryotic cell under optimal conditions, Zn associates with protein forming Zn finger. A Zn finger is a small protein structural motif, characterized by the co-ordination of one or more zinc ions in order to stabilize the protein fold. Zn fingers bind RNA and mediate protein-protein interactions. A Zn finger protein was found to inhibit influenza virus replication [36, 37, 38, 39]. Under experimental conditions, Zn combines with TMP forming fixed complex preserving the anti-bacterial properties of TMP but without evidence of anti-virus [40, 41]. Whereas, in-vivo, the non-fixed formulation of Zn and TMP (Tri-Z) inhibited influenza virus in chick embryo, similar to that in man [8], enabling embryo survival of infection. The viral inhibition of Tri-Z appears to be ratio dependent. We found that increasing ratio of Zn to TMP increased embryo survival, until an optimal ratio was reached, then embryo survival decreased with further increase in ratio. Increasing viral load from 10 EID₅₀ to 100 EID₅₀ reduced the range of the ratio that enables embryo survival. However, the optimal ratio remained unchanged. The ratio dependence indicates presence of an interaction between the two molecules when certain conditions are met. For example, in water, the pH of the combination at the optimal ratio of 0.18 is 7.24 which is the pKa of TMP. For TMP, pH = pKa + Log₁₀ (protonated / unprotonated compound), as pH = pKa, then the ratio of protonated to unprotonated TMP is 1. Such equilibrium in the charge of TMP is expected to allow association with Zn in a dynamic combination. Dynamic interactions between drugs were shown to occur at equilibrium and enhance its permeability across biological membrane to target RNA [42, 43]. This, perhaps, is similar to the Zn finger protein phenomenon.

Once introduced, the virus is not shed out of the egg. Inability of the virus to infect suggested that Tri-Z prevented these infections from occurring. A possible mechanism of action is interfering with virus binding to its cell surface sialic acid-based receptor [44]. Virus binding to this receptor is a process by which HA occurs [23]. At ratio 0.18 Zn to TMP, hemagglutination inhibition was possible. Previous studies showed a relationship between pharmacokinetics of TMP and sialic acid rich protein [45, 46]. Therefore, it seems that Tri-Z acts at multiple sites whereby the RNA virus utilizes the host to infect and replicate including the virus ability to bind to its cell surface receptor.

It may be thought that increasing use of TMP in this combination might increase bacterial resistance. TMP is a long-standing drug which is widely used and spread in the environment without emergence of new resistance [47].

Conclusions

We conclude that a combination of Zn and TMP enables chick embryo survival of influenza virus infection which is ratio dependent. At optimal ratio, the combination acts on host cells including cell surface receptor whereby it inhibits the virus from binding to its cell surface receptor. Further studies to examine the use of Tri-Z in treating patients infected with other respiratory RNA viruses are planned.

List Of Abbreviations

TMP = trimethoprim
Tri-Z = trimethoprim and zinc combination
Zn= zinc
HA = hemagglutination
HAI = hemagglutination inhibition
HAU = hemagglutination unit
ml = milliliter
RBC= red blood cells
EID = egg infective dose
°C = degree centigrade
WHO = world health organization
FIA = fluorescence immune assay
RT-PCR = reverse transcription polymerase chain reaction
RNA = ribonucleic acid
DNA = deoxyribonucleic acid
PBS = phosphate buffered saline

Declarations

Ethics approval and consent to participate
All work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. All animal experiments are carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines.

Consent to publication
No applicable

Availability of data and material
All data are presented in the results section and expressed into graphic presentations. If any data, not already shared, are needed it may be made available.

Competing interests
There is no competing interest.

Funding
The studies were funded by Her Majesty’s Revenue and Customs’ research and development tax relief and credit system.

Authors’ contributions
All authors contributed equally to the study and preparing the manuscript. They read and approve the manuscript for publication.

Acknowledgements
We thank Mr Damien Bove for his guidance and support in putting the studies together.

References
1. Drake JW, Holland JJ: Mutation rates among RNA viruses. Proceedings of the National Academy of Sciences of the United States of America. 1999, 96: 13910–13913.
2. Shaw ML, Palese P: Orthomyxoviridae. in Knipe DM, Howley PM, editors. FIELD’S VIROLOGY; Sixth Edition, Lippincott Williams & Will, 2013 London, ISBN: 10:1-4522-0563-0
3. Bush RM: Inuenza as a model system for studying the cross-species transfer and evolution of the SARS coronavirus. Philos Trans R Soc Lond B Biol Sci. 2004, 359 (1447):1067-1073. doi:10.1098/rstb.2004.1481
4. Riedel S: Crossing the species barrier: the threat of an avian influenza pandemic. Proc Bayl Univ Med Cent. 2006, 19: 16–20.
5. Nishino T, Wecke J, Krüger D, Giesbrecht P: Trimethoprim-induced structural alterations in Staphylococcus aureus and the recovery of bacteria in drug-free medium, Journal of Antimicrobial Chemotherapy 1987, 19 (2): 147–159,
6. Sive J, Green R, Metz J: Effect of trimethoprim on folate-dependent DNA synthesis in human bone marrow. J. clin. Path. 1972, 25: 194-197.
7. Korant BD, Kauer JC, Butterworth BE: Zn ions inhibit replication of rhinoviruses. Nature 1974, 248: 588-90.
8. El Habbal MH. Zinc/Trimethoprim combination therapy. WO 2009/109531 (11.09.2009 Gazette 2009/37). https://patentimages.storage.googleapis.com/6f/ee/13/555aad4085f57/EP2257292B1.pdf
9. Hodinka RL: Respiratory RNA Viruses, in, Diagnostic Microbiology of the Immunocompromised Host 2e Edited by Hayden RT, Wolk DM, Carroll KC, and Yi-Wei Tang Y. American Society for Microbiology, 2016 Washington, DC. doi:10.1128/microbiolspec.DMIH2-0028-2016
10. Straube EF, Schuster NH, Sinclair AJ: Zinc toxicity in the ferret. Journal of Comparative Pathology 1980, 90: 355-361.
11. Sun X, Lu L, Liao X, Zhang L, Lin X, Luo X, Ma Q: Effect of In Ovo Zinc Injection on the Embryonic Development and Epigenetics-Related Indices of Zinc-Deprived Broiler Breeder Eggs. Biol Trace Elem Res. 2018, 185: 456-464.
12. Berg, J. M. & Shi, Y: The galvanization of biology: a growing appreciation for the roles of Zn. Science 1996, 271: 1081–1085.
13. Naz S, Idris M, Khaliq MA, Zia-Ur-Rahman, Alhady IA, AbdeLRahman MM, Khan RU, Chand N, Farooq U, Ahmad S: The activity and use of zinc in poultry diets. World's Poultry Science Journal 2016, 72: 159-167.
14. Watson BK, Coons AH: Studies of influenza virus infection in the chick embryo using fluorescent antibody. J Exp Med 1954, 99:419-428. doi:10.1084/jem.99.5.419
15. Wang JX, Zhou JY, Yang QW, Chen Y, Li X, Piao YA, Li HY: An improved embryonated chicken egg model for the evaluation of antiviral drugs against influenza A virus. J Virol Methods 2008, 153 (2):218-222.
16. CDC protocol of realtime RTPCR for influenza A (H1N1). http://www.who.int/csr/resources/publications/swineflu/CDCRetartimeRTPCR_SwineH1Assay-2009-20090430.pdf
17. WHO manual on animal influenza, diagnosis and surveillance. WHO/CD6/CSR/NCS/2002.51
18. Lee MS, Chang PC, Shien JH, Cheng MC, Shieh HK: Identification and subtyping of avian influenza viruses by reverse transcription-PCR. J Virol Methods 2001, 97:13-22.
19. Sauerbrei A, Haertl A, Brandstaedt A, Schmidtke M, Wutzler P: Utilization of the embryonated egg for in vivo evaluation of the anti-influenza virus activity of neuraminidase inhibitors. Med Microbiol Immunol 2006,195: 65–71.
20. Recommended laboratory tests to identify avian influenza A virus in specimens from humans. 2005. https://biosafety.sinica.edu.tw/Recommended%20laboratory%20tests%20to%20identify%20avian%20influenza%20A%20virus%20in%20specimens%20for
21. Hirst GK: Direct isolation of human influenza virus in chick embryos. J Immunol 1942, 45:293-302.
22. Hamburger V, Hamilton HL: A series of normal stages in the development of the chick embryo. Journal of Morphology 1951, 88: 49 -92.
23. Hirst GK: The quantitative determination of influenza virus and antibodies by means of red cells agglutination. J Exp Med 1942, 75:49-64.
24. Dowdle WA, Kendal AP, Nobel G.: Influenza virus. in Lennette EH, Schmidt NJ (editors). Diagnostic Procedures for Viral, Rickettsial and Chlamydial Infections. 5th edition, American Public Health Association, Inc. 1979; pages 385-609.
25. Reed LJ and Muench H: A simple method of estimating fifty per cent endpoints. American Journal of Epidemiology 1938, 27:493-497.
26. Morahan PS, Grossberg SE: Age-related cellular resistance of the chicken embryo to viral infections. I. Interferon and natural resistance to myxoviruses and vesicular stomatitis virus. The journal of Infectious Diseases 1970, 121:615-623.
27. Sauerbrei A, Haertl A, Brandstaedt A, Schmidtke M, Wutzler P: Utilization of the embryonated egg for in vivo evaluation of the anti-influenza virus activity of neuraminidase inhibitors. Med Microbiol Immunol 2006, 195: 65–71.
28. Bewick V, Cheek L, Ball J: Statistics review 12: Survival analysis. Critical Care 2004, 8:389-394.
29. Bland M: An introduction to medical statistics. 2nd edition, Oxford University Press. 1995.
30. Kalter SS. Amino acids present in allantoic fluid proteins from chick embryos infected with influenza virus. J Immunol 1950, 64:499-504.
31. Follett EAC, Pringle CR, Wunner WH, Skehel JJ: Virus replication in enucleate cells: vesicular stomatitis virus and influenza virus. Journal of Virology 1974, 13: 394-399.
32. Kelly DC, Avery RJ, Dimmock NJ: Failure of an influenza virus to initiate infection in enucleate cells. Journal of Virology 1974, 13: I155-I161.
33. Floret O, Marcialis NA, Firinu A, Bertolini A: Inhibitory action of 2,4 diamino 5 (3,4,5 trimethoxybenzyl) pyrimidine (TMP) on the growth of DNA viruses. Rivista di Farmacologia e Therapica 1974, 5: 201-204.
34. Goldberg S, Soniji A, Marks NJ: Inhibition of herpes virus replication by trimethoprim and co-trimethoxazole. Clinical Research 1976, 24:676A.
35. Jackson JL, Lesho E, Peterson C. Zn and the Common Cold: A Meta-Analysis Revisited. J. Nutr. 2000, 130: 1512S—1515S.
36. Reed LJ and Muench H: A simple method of estimating fifty per cent endpoints. American Journal of Epidemiology 1938, 27:493-497.
37. Sauerbrei A, Haertl A, Brandstaedt A, Schmidtke M, Wutzler P: Utilization of the embryonated egg for in vivo evaluation of the anti-influenza virus activity of neuraminidase inhibitors. Med Microbiol Immunol 2006, 195: 65–71.
38. Bewick V, Cheek L, Ball J: Statistics review 12: Survival analysis. Critical Care 2004, 8:389-394.
39. Bland M: An introduction to medical statistics. 2nd edition, Oxford University Press. 1995.
40. Kalter SS. Amino acids present in allantoic fluid proteins from chick embryos infected with influenza virus. J Immunol 1950, 64:499-504.
41. Follett EAC, Pringle CR, Wunner WH, Skehel JJ: Virus replication in enucleate cells: vesicular stomatitis virus and influenza virus. Journal of Virology 1974, 13: 394-399.
42. Kelly DC, Avery RJ, Dimmock NJ: Failure of an influenza virus to initiate infection in enucleate cells. Journal of Virology 1974, 13: I155-I161.
43. Floret O, Marcialis NA, Firinu A, Bertolini A: Inhibitory action of 2,4 diamino 5 (3,4,5 trimethoxybenzyl) pyrimidine (TMP) on the growth of DNA viruses. Rivista di Farmacologia e Therapica 1974, 5: 201-204.
44. Goldberg S, Soniji A, Marks NJ: Inhibition of herpes virus replication by trimethoprim and co-trimethoxazole. Clinical Research 1976, 24:676A.
45. Jackson JL, Lesho E, Peterson C. Zn and the Common Cold: A Meta-Analysis Revisited. J. Nutr. 2000, 130: 1512S—1515S.
46. Lin RJ, Huang CH, Liu PC, Lin IC, Huang YL, Chen AY, Chiu HP, Shih SR, Lin LH, Lien SP, Yen LC, Liao CL: Zinc finger protein ZFP36L1 inhibits influenza A virus through translational repression by targeting HA, M and NS RNA transcripts. Nucleic Acids Res 2020, 48 (13): 7371-7384.
47. Hui EKW, Smee DF, Wong MH, Nayak DP: Mutations in influenza virus M1 CCHH, the Putative Zn Finger Motif, Cause attenuation in mice and protect mice against lethal influenza virus infection. J Virol 2001, 97:13-22.
48. Reed LJ and Muench H: A simple method of estimating fifty per cent endpoints. American Journal of Epidemiology 1938, 27:493-497.
49. Hirst GK: Direct isolation of human influenza virus in chick embryos. J Immunol 1942, 45:293-302.
50. Hamburger V, Hamilton HL: A series of normal stages in the development of the chick embryo. Journal of Morphology 1951, 88: 49 -92.
51. Hirst GK: The quantitative determination of influenza virus and antibodies by means of red cells agglutination. J Exp Med 1942, 75:49-64.
52. Dowdle WA, Kendal AP, Nobel G.: Influenza virus. in Lennette EH, Schmidt NJ (editors). Diagnostic Procedures for Viral, Rickettsial and Chlamydial Infections. 5th edition, American Public Health Association, Inc. 1979; pages 385-609.
53. Reed LJ and Muench H: A simple method of estimating fifty per cent endpoints. American Journal of Epidemiology 1938, 27:493-497.
42. Corbett PT, Leclaire J, Vial L, West KR, Wietor JL, Sanders JKM, Otto S: Dynamic combinatorial chemistry. Chem. Rev. 2006, 106:3652–3711.
43. McAnany JD, Miller BL: Dynamic combinatorial chemistry as a rapid method for discovering sequence-selective RNA-binding compounds. Methods Enzymol 2019, 623:67-84.
44. Weis W, Brown JH, Cusack S, Paulson JC, Skehel JJ, Wiley DC: The structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid. Nature 1988, 333:426-431.
45. Tagawa Y, Kokue E, Shimoda M, Son DS: α1-acid glycoprotein-binding as a factor in age-related changes in the pharmacokinetics of TMP in piglets. Veterinary Quarterly 1994, 16:13-17.
46. Son DS, Shimoda M, Kokve E: Implication of altered levels of plasma alpha(1)-acid glycoprotein and its derived sialic acid on plasma protein binding of TMP in pigs in physiological and pathological states. Veterinary Quarterly 1996, 18:10-3.
47. Straub JO: An Environmental Risk Assessment for Human-Use TMP in European Surface Waters. Antibiotics 2013, 2: 115-162.